YOLFTbeta
Rezolute Inc

Rezolute Inc

RZLT · NASDAQ · Healthcare / Biotechnology

3.66USD-0.22 (-5.56%)

Price History

Full chart

Market Stats

Previous Close3.87
Open4.56
Day Range3.60 – 4.61
52-Week Range1.07 – 11.46
Volume5.73M
Market Cap404.30M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.75
Dividend Yield0.00%
Beta0.61
50-Day Avg4.57
200-Day Avg3.70

About

Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Daron G. Evans M.B.A., M.S.
  • Employees58
  • Headquarters275 Shoreline Drive, Redwood City, CA, United States, 94065, USA
  • Websitehttps://www.rezolutebio.com

Leadership

  • Mr. Daron G. Evans M.B.A., M.S.Chief Financial & Business Officer · b. 1974
  • Mr. Chris MilksVP & Head of Finance

Financials

Income Statement

Currency: USD2012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue--000000000000-
Cost of Revenue4.84K4.56M2.40M5.85M8.27M12.57M048.00K18.00K13.00K256.00K382.00K36.00K31.00K31.00K
Gross Profit-4.84K-4.56M-2.40M-5.85M-8.27M-12.57M0-48.00K-18.00K-13.00K-256.00K-382.00K-36.00K-31.00K-31.00K
Operating Expense40.89K1.55M2.78M4.85M6.68M7.75M28.73M25.90M20.50M22.88M41.59M55.61M70.39M79.86M82.94M
Operating Income-45.73K-6.11M-5.18M-10.70M-14.95M-20.32M-28.73M-25.94M-20.52M-22.89M-41.84M-55.99M-70.42M-79.89M-82.97M
EBITDA-45.51K-6.16M-5.49M-11.22M-14.18M-19.16M-25.18M-25.44M-20.32M-20.51M-39.24M-51.76M-68.42M-74.38M-82.97M
Net Income-49.29K-6.73M-9.73M-11.36M-14.94M-20.28M-29.86M-30.42M-20.33M-20.90M-41.06M-51.79M-68.46M-74.41M-77.59M
R&D-3.49K34.32K4.70M9.45M12.09M17.28M19.08M14.45M14.99M32.49M43.81M55.74M61.53M53.80M
Interest Expense0568.86K4.23M6.73K5.04K1.59K689.19K4.96M12.00K375.00K1.81M919.00K---

Balance Sheet

Currency: USD2012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets1.07M1.10M7.40M11.26M10.90M10.63M2.50M12.25M10.96M42.61M152.42M123.72M132.74M175.49M112.85M
Total Liabilities2.36M5.27M997.92K2.21M2.13M2.10M6.46M10.50M3.60M16.51M2.95M7.55M11.73M13.36M12.16M
Total Equity-1.29M-4.16M6.41M9.05M8.77M8.53M-3.96M1.75M7.37M26.10M149.47M116.17M121.00M162.13M100.69M
Cash25.88K5275.93M5.28M4.06M4.49M1.65M11.57M9.96M41.05M150.41M16.04M70.40M94.11M10.62M
Total Debt2.14M3.73M60.00K176.98K83.13K10.00K3.43M10.00K410.00K14.42M515.00K2.48M2.23M1.61M934.00K
Net Debt2.11M3.73M-5.87M-5.10M-3.98M-4.48M1.79M-11.56M-9.54M-26.63M-150.22M-13.56M-68.17M-92.49M-9.68M

Cash Flow

Currency: USD2012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow-40.40K-1.63M-3.17M-7.08M-10.49M-13.31M-14.11M-15.30M-24.17M-20.44M-39.62M-44.48M-57.37M-69.08M-64.64M
Investing Cash Flow-2.00K185.11K-830.18K-3.61M-1.45M-195.38K1.73M231.00K-101.46M-101.46M-101.46M-101.46M48.70M-14.54M-21.10M
Financing Cash Flow10.50K1.42M9.93M10.04M10.73M13.93M9.54M25.00M22.55M51.53M148.98M11.57M63.03M107.33M2.24M
Capital Expenditure2.00K11.72K69.97K3.16M2.09M407.93K5.82K47.00K153.00K153.00K153.00K153.00K000
Free Cash Flow-42.40K-1.64M-3.24M-10.24M-12.58M-13.72M-14.12M-15.35M-24.17M-20.44M-39.62M-44.63M-57.37M-69.08M-64.64M
FCF to OCF104.95%100.72%102.21%144.68%119.94%103.06%100.04%100.31%100.00%100.00%100.00%100.34%100.00%100.00%100.00%

Earnings

Report DateSep 30, 2012Dec 31, 2012Mar 31, 2013Sep 11, 2013Nov 12, 2013Feb 13, 2014May 14, 2014Sep 30, 2014Nov 12, 2014Feb 17, 2015May 15, 2015Jun 30, 2015Nov 16, 2015Feb 16, 2016May 16, 2016Sep 28, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Sep 22, 2017Nov 14, 2017Feb 14, 2018May 15, 2018Jun 30, 2018Dec 14, 2018Feb 14, 2019May 10, 2019Sep 10, 2019Nov 14, 2019Feb 12, 2020May 14, 2020Sep 2, 2020Nov 12, 2020Feb 10, 2021May 17, 2021Sep 15, 2021Nov 12, 2021Feb 9, 2022May 12, 2022Sep 15, 2022Nov 9, 2022Feb 10, 2023May 11, 2023Sep 14, 2023Nov 13, 2023Feb 13, 2024May 15, 2024Sep 19, 2024Nov 7, 2024Feb 12, 2025May 13, 2025Sep 17, 2025Nov 6, 2025Feb 12, 2026May 13, 2026Sep 24, 2026Nov 5, 2026
EPS Estimate-------7.00--6.00-5.00-7.50--7.00-7.50-9.00-7.50------------1.50-1.00-1.00-1.00-0.61-0.84-0.75-0.78-0.80-0.89-0.66-0.97-0.41-0.35-0.32-0.30-0.36-0.28-0.29-0.32-0.33-0.34-0.26-0.24-0.21-0.26-0.18-0.17-0.14-0.14
EPS Actual-0.12-0.02-35.41-0.15-0.12-0.27-38.00-0.11-6.00-8.00-7.00-6.24-7.00-8.50-7.50-19.00-5.39-5.99-10.36-0.13-0.13-0.11-0.09-10.50-0.20-0.07-0.32-2.00-1.00-1.00-1.00-0.60-0.62-0.88-0.66-0.78-0.92-0.80-0.65-0.37-0.19-0.26-0.30-0.25-0.28-0.27-0.34-0.44-0.22-0.22-0.27-0.26-0.18-0.22-0.16-0.20-
Surprise-------442.86%-0.00%-60.00%6.67%-0.00%-13.33%16.67%-153.33%------------33.33%0.00%0.00%0.00%0.82%26.19%-17.33%15.38%2.50%-3.37%-21.21%32.99%9.76%45.71%18.75%0.00%30.56%0.00%6.90%-6.25%-33.33%35.29%15.38%-12.50%-21.89%30.77%-22.22%7.99%-42.86%-
Timing---After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hours---Pre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-After-hoursAfter-hours

Key Statistics & Ratios

Market Cap404.30M
Enterprise Value266.01M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book3.30
EPS-0.75
Book Value1.12
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-81.44M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-59.04%
Return on Assets-35.32%
Shares Outstanding96.72M
Shares Float60.90M
Beta0.61
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 10 analystsTarget 8.33
  • Strong Buy
    7
  • Buy
    3

Ownership Breakdown

Institutions
98.37%
Insiders
10.10%
Retail / Other
0.00%

Top Institutional Holders

  • Federated Hermes Inc
    12.99M13.49%
  • RA Capital Management, LLC
    9.18M9.53%
  • BlackRock Inc
    6.31M6.56%
  • Opaleye Management Inc
    6.30M6.54%
  • Balyasny Asset Management LLC
    5.05M5.24%
  • Vanguard Capital Management, LLC
    3.52M3.66%
  • Siren, L.L.C.
    3.33M3.46%
  • Vanguard Portfolio Management, LLC
    2.98M3.10%
  • Bank of America Corp
    2.97M3.08%
  • Morgan Stanley - Brokerage Accounts
    2.75M2.85%
  • Jennison Associates LLC
    2.46M2.55%
  • Geode Capital Management, LLC
    1.96M2.04%
  • UBS Group AG
    1.94M2.01%
  • D. E. Shaw & Co LP
    1.84M1.91%
  • State Street Corp
    1.77M1.84%
  • Kennedy Capital Management Inc
    1.22M1.27%

Top Fund Holders

  • Federated Hermes Kaufmann R
    8.49M8.81%
  • Federated Hermes Kaufmann Small Cap A
    6.18M6.41%
  • Vanguard MStar Total Stk Mkt Idx Invest
    2.74M2.85%
  • iShares Russell 2000 ETF
    2.03M2.11%

Stock Splits

  • Oct 13, 20201:50
  • May 1, 20141:6
  • Jan 10, 2013501503:83584